OncoMatch

OncoMatch/Clinical Trials/NCT07733674

Phase I Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Solid Tumors Like GBM and PDAC

Is NCT07733674 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies 203Pb-RMX-VHPIB for glioblastoma multiforme (gbm).

Phase 1RecruitingRadiomedix, Inc.NCT07733674Data as of Sep 2026

Treatment: 203Pb-RMX-VHPIBThe goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: How does 203Pb-RMX-VH-PIB spread in the body (biodistribution)? What is the radiation dose delivered to organs (dosimetry)? Participants will: Receive a single IV injection of 203Pb-RMX-VH-PIB. Undergo multiple SPECT/CT imaging scans. Have blood, urine, vital signs, and ECG monitored for safety. Be followed for any side effects for up to 30 days.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

203Pb-RMX-VHPIB

Cancer type

Glioblastoma

Pancreatic Cancer

Lab requirements

Blood counts

WBC: ≥ 2 x 10^9/L; Haemoglobin: ≥ 8 g/dL; Platelets: ≥75 x 10^9/L

Kidney function

Creatinine clearance ≥ 60 mL/min, calculated by the Cockcroft-Gault equation

Liver function

ALT, AST, AP ≤ 5 times ULN; Bilirubin: ≤ 2 times ULN

Recent blood test results (within 4 weeks pre-dose): WBC: ≥ 2 x 10^9/L; Haemoglobin: ≥ 8 g/dL; Platelets: ≥75 x 10^9/L; ALT, AST, AP ≤ 5 times ULN; Bilirubin: ≤ 2 times ULN; Creatinine clearance ≥ 60 mL/min, calculated by the Cockcroft-Gault equation

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Excel Diagnostics & Nuclear Oncology Center · Houston, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT07733674 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify